Recent News

• 03.11.2025 - Nuwellis, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results
• 03.11.2025 - Nuwellis, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results
• 02.24.2025 - Nuwellis Announces Retirement of Nestor Jaramillo, Jr. as President and CEO
• 02.24.2025 - Nuwellis Announces Retirement of Nestor Jaramillo, Jr. as President and CEO
• 02.20.2025 - JACC: Heart Failure Paper Reports Promising Findings of Aquadex Therapy in Updated AVOID-HF Study Analysis
• 02.20.2025 - JACC: Heart Failure Paper Reports Promising Findings of Aquadex Therapy in Updated AVOID-HF Study Analysis
• 02.18.2025 - Nuwellis, Inc. To Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025
• 02.18.2025 - Nuwellis, Inc. To Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025
• 01.13.2025 - Nuwellis Adds Nationally Ranked Utah Hospital as New Pediatric Customer for Aquadex SmartFlow® Therapy
• 01.13.2025 - Nuwellis Adds Nationally Ranked Utah Hospital as New Pediatric Customer for Aquadex SmartFlow® Therapy

Recent Filings

• 03.11.2025 - EX-99.1 EX-99.1
• 03.11.2025 - 8-K Current report
• 03.11.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.24.2025 - EX-99.1 EX-99.1
• 02.24.2025 - 8-K Current report
• 12.20.2024 - EFFECT Notice of Effectiveness
• 12.20.2024 - 424B3 Prospectus [Rule 424(b)(3)]
• 12.20.2024 - CORRESP Correspondence